The Use of Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Muscular Dystrophies: Results from Compassionate Use in Real-Life Settings
Open Access
- 27 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (10) , 1372-1383
Abstract
Muscular dystrophies are genetically determined progressive diseases with no cause-related treatment and limited supportive treatment. Although stem cells cannot resolve the underlying genetic conditions, their wide-ranging therapeutic properties may ameliorate the consequences of the involved mutations (oxidative stress, inflammation, mitochondrial dysfunction, necrosis). In this study, we administered advanced therapy medicinal product containing umbilical cord-derived mesenchymal stem cells (UC-MSCs) to 22 patients with muscular dystrophies. Patients received one to five intravenous and/or intrathecal injections per treatment course in up to two courses every 2 months. Four standard doses of 10, 20, 30, or 40 × 106 UC-MSCs per injection were used; the approximate dose per kilogram was 1 × 106 UC-MSCs. Muscle strength was measured with a set of CQ Dynamometer computerized force meters (CQ Elektronik System, Czernica, Poland). Statistical analysis of muscle strength in the whole group showed significant improvement in the right upper limb (+4.0 N); left hip straightening (+4.5 N) and adduction (+0.5 N); right hip straightening (+1.0 N), bending (+7.5 N), and adduction (+2.5 N); right knee straightening (+8.5 N); left shoulder revocation (+13.0 N), straightening (+5.5 N), and bending (+6.5 N); right shoulder adduction (+3.0 N), revocation (+10.5 N), and bending (+5 N); and right elbow straightening (+9.5 N); all these differences were statistically significant. In six patients (27.3%) these changes led to improvement in gait analysis or movement scale result. Only one patient experienced transient headache and lower back pain after the last administration. In conclusion, UC-MSC therapy may be considered as a therapeutic option for these patients.Keywords
Funding Information
- Polski Bank Komórek Macierzystych S.A.
This publication has 70 references indexed in Scilit:
- Tadalafil Alleviates Muscle Ischemia in Patients with Becker Muscular DystrophyScience Translational Medicine, 2012
- Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2HJournal of Clinical Investigation, 2012
- Increased muscle expression of interleukin-17 in Duchenne muscular dystrophyNeurology, 2012
- New Dystrophin/Dystroglycan interactors control neuron behavior in Drosophila eyeBMC Neuroscience, 2011
- Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humansJournal of Bone and Mineral Research, 2011
- Pro-Inflammatory Cytokines, IFNγ and TNFα, Influence Immune Properties of Human Bone Marrow and Wharton Jelly Mesenchymal Stem Cells DifferentiallyPLOS ONE, 2010
- Satellite cell dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1Neuropathology and Applied Neurobiology, 2009
- Isolation and Characterization of Mesoangioblasts from Facioscapulohumeral Muscular Dystrophy Muscle BiopsiesStem Cells, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Specific Disruption of a Schwann Cell Dystrophin-Related Protein Complex in a Demyelinating NeuropathyNeuron, 2001